Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab for resectable gastric cancer or non-small cell lung cancer
jRCT2080223839Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in gastric adenocarcinoma and non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223839.